Literature DB >> 13910443

Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PAS.

J B SELKON, W FOX, P R GANGADHARAM, K RAMACHANDRAN, C V RAMAKRISHNAN, S VELU.   

Abstract

A series of studies on the rate of inactivation of isoniazid in Indian patients with pulmonary tuberculosis undergoing domiciliary chemotherapy with isoniazid, alone or in combination with p-aminosalicylic acid, has recently been undertaken by the Tuberculosis Chemotherapy Centre, Madras. In the first study, the serum isoniazid levels of the patients were determined four-and-a-half hours after intramuscular administration of a standard dose of 3 mg/kg body-weight of isoniazid and, according to whether the serum level was 0.58 mug/ml or above, or less than 0.58 mug/ml, the patient was classified as a slow or as a rapid inactivator. The present paper describes the second of these studies, in which the response to treatment of the slow and the rapid inactivators was compared. The results of this investigation suggested that there might be an association between response to treatment and rate of inactivation of isoniazid, since the slow inactivators were more often culture-negative during treatment and showed a higher proportion of individuals with bacteriologically quiescent disease at 12 months and a lower proportion with radiographic deterioration at six months than the rapid inactivators, while the slow inactivators who deteriorated radiographically or clinically to an extent warranting a change of treatment during the two years did so later than the corresponding rapid inactivators. There was slight evidence that the slow and the rapid inactivators differed in the speed of conversion to bacteriological negativity of those patients whose disease was bacteriologically quiescent at 12 months, but no evidence that they differed in the degree of positivity of sputum specimens that were positive on culture at six, nine or 12 months, or in the frequency with which the patients showed moderate or greater radiographic improvement at six months.

Entities:  

Keywords:  ISONIAZID/metabolism; TUBERCULOSIS, PULMONARY/therapy

Mesh:

Substances:

Year:  1961        PMID: 13910443      PMCID: PMC2555638     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  10 in total

1.  Observations on the pathogenicity of isoniazid-resistant mutants of tubercle bacilli for tuberculous patients.

Authors:  R OESTREICHER; S H DRESSLER; W F RUSSELL; J B GROW; G MIDDLEBROOK
Journal:  Am Rev Tuberc       Date:  1955-03

2.  Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of domiciliary chemotherapy, and influence of further chemotherapy on the relapse rate.

Authors:  S VELU; R H ANDREWS; J H ANGEL; S DEVADATTA; W FOX; P R GANGADHARAM; A S NARAYANA; C V RAMAKRISHNAN; J B SELKON; P R SOMASUNDARAM
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

3.  Genetic control of isoniazid metabolism in man.

Authors:  D A EVANS; K A MANLEY; V A McKUSICK
Journal:  Br Med J       Date:  1960-08-13

4.  Examination of smears for tubercle bacilli by fluorescence microscopy.

Authors:  E HOLST; D A MITCHISON; S RADHAKRISHNA
Journal:  Indian J Med Res       Date:  1959-09       Impact factor: 2.375

5.  Clinical implications of isoniazid blood levels in pulmonary tuberculosis.

Authors:  R S MITCHELL; J C BELL
Journal:  N Engl J Med       Date:  1957-11-28       Impact factor: 91.245

6.  Serum isoniazid levels and catalase activities of tubercle bacilli from isoniazid-treated patients.

Authors:  M L COHN; W MANDEL; G MIDDLEBROOK; W F RUSSELL
Journal:  Am J Med Sci       Date:  1957-01       Impact factor: 2.378

7.  Studies on isoniazid and tubercle bacilli. II. The growth requirements, catalase activities, and pathogenic properties of isoniazid-resistant mutants.

Authors:  M L COHN; C KOVITZ; U ODA; G MIDDLEBROOK
Journal:  Am Rev Tuberc       Date:  1954-10

8.  The virulence in the guinea-pig of tubercle bacilli isolated before treatment from South Indian patients with pulmonary tuberculosis. I. Homogeneity of the investigation and a critique of the virulence test.

Authors:  D A MITCHISON; A L BHATIA; S RADHAKRISHNA; J B SELKON; T V SUBBAIAH; J G WALLACE
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

9.  Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis.

Authors:  P R GANGADHARAM; A L BHATIA; S RADHAKRISHNA; J B SELKON
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

10.  Peripheral neuritis due to isoniazid.

Authors:  S DEVADATTA; P R GANGADHARAM; R H ANDREWS; W FOX; C V RAMAKRISHNAN; J B SELKON; S VELU
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

  10 in total
  11 in total

1.  Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

Review 2.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

3.  The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis: 1. An assessment of two vitamin B preparations and glutamic acid.

Authors: 
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

4.  Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis.

Authors:  P R GANGADHARAM; A L BHATIA; S RADHAKRISHNA; J B SELKON
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

5.  Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS.

Authors:  P R GANGADHARAM; S DEVADATTA; W FOX; C N NAIR; J B SELKON
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

6.  THE PREVENTION AND TREATMENT OF ISONIAZID TOXICITY IN THE THERAPY OF PULMONARY TUBERCULOSIS. 2. AN ASSESSMENT OF THE PROPHYLACTIC EFFECT OF PYRIDOXINE IN LOW DOSAGE.

Authors:  L A ZILBER; Z L BAJDAKOVA; A N GARDASJAN; N V KONOVALOV; T L BUNINA; E M BARABADZE
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

7.  Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid.

Authors:  K V Rao; D A Mitchison; N G Nair; K Prema; S P Tripathy
Journal:  Br Med J       Date:  1970-08-29

8.  THE EMERGENCE OF ISONIAZID-RESISTANT CULTURES IN PATIENTS WITH PULMONARY TUBERCULOSIS DURING TREATMENT WITH ISONIAZID ALONE OR ISONIAZID PLUS PAS.

Authors:  J B SELKON; S DEVADATTA; K G KULKARNI; D A MITCHISON; A S NARAYANA; C N NAIR; K RAMACHANDRAN
Journal:  Bull World Health Organ       Date:  1964       Impact factor: 9.408

9.  Role of pharmacogenomics in the treatment of tuberculosis: a review.

Authors:  Geetha Ramachandran; Soumya Swaminathan
Journal:  Pharmgenomics Pers Med       Date:  2012-09-13

10.  Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients.

Authors:  Ana Requena-Méndez; Geraint Davies; David Waterhouse; Alison Ardrey; Oswaldo Jave; Sonia Llanet López-Romero; Stephen A Ward; David A J Moore
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.